The earnings result
Alnylam Pharmaceuticals reported earnings on 2022-07-28 for the fiscal quarter ending Jun/2022. Reported EPS of $-2.29 compared with a consensus estimate of $-1.62, a miss on the source's earnings measure.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: report-date close; announcement time unavailable. The source does not identify whether this report was before or after trading. These are subsequent daily returns, not a verified immediate earnings reaction.
The first measured session returned -1.03% from the stated baseline. The five-session return was +56.11%, and the 20-session return was +49.05%. SPY returned +3.31% across the corresponding window. Relative volume was 0.96 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.